A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (KANDOVA)

Inclusion Criteria: Histologically verified high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer Participants must have recurrent disease, defined as: 1st relapse 3 to 6 months after completion of the last dose of primary platinum containing treatment, or 2nd or 3rd relapse within 6 months after completion of the last dose of the latest platinum-containing regimen (platinum-free interval within 6 months) Participants must have had platinum-based chemotherapy in the first-line setting (primary treatment) For BRCA status, samples must be available for analysis; for HRD status, samples should be available for analysis, if possible. If not already analyzed, the subject agrees to undergo analysis of HRD and BRCA status on primary tumor tissue and/or recurrent tumor tissue ECOG performance status 0-2 Subjects must have at least 1 measurable disease according to RECIST 1.1 guidelines Able to take oral medications Adequate organ function: Absolute neutrophil count ≥ 1.5 x 10^9/L, Platelets > 100 x 10^9/L, Hemoglobin ≥ 80 g/dl, Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula, Total bilirubin ≤ 1.5 x ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN, and Serum albumin ≥ 30 g/L. Consent to biopsy taken prior to starting treatment and Week 8 (± 1 week) of treatment At least 18 years of age Life expectancy of at least 12 weeks Women of childbearing potential must use adequate birth control Willingness and ability to comply with study procedures, visit schedules, study restrictions and requirements Able to fully understand and participate in study-related procedures, including compliance and patient reported outcome Written informed consent. Subjects must give informed consent prior to any study-specific procedure Exclusion Criteria: Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers, and cancer types not mentioned in the inclusion criteria Primary platinum-refractory disease, defined as tumor progression during or within 12 weeks from end of first platinum treatment Concurrent cancer therapy Received other than platinum-containing therapy for primary disease (first-line treatment) Received non-platinum-containing chemotherapy in recurrent setting Treatment with an investigational agent concurrently, or within the past 3 months Previous malignant disease: subjects are not eligible for the study if actively being treated for invasive cancer other than ovarian cancer Immunodeficiency or organ transplant. Autoimmune or inflammatory condition that requires immunosuppressive or steroid therapy during the course of the study Live vaccines within 28 days prior to the first IMP dose Major surgery within 28 days prior to the first IMP dose, or not recovered from previous surgery to CTCAE (v5) grade 1 equivalent Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) Transient ischemic attack (TIA) or stroke, including bleeding, within the past 6 months Brain and/or liver metastases Major cardiac dysfunction defined as > NYHA II Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug Serious, uncontrolled, and active infection at enrollment, as determined by the Investigator Pregnancy or breastfeeding Persistence of clinically relevant therapy-related toxicity from previous chemotherapy (any grade 3-4 toxicity or grade ≥ 2 neuropathy) Current use of drugs sensitive to CYP3A4 inhibition which cannot be paused or switched to an alternative within the same class of medication for the period of IMP administration Continuous use of herbal preparations (e.g., St. John's wort) within 2 weeks prior to enrollment Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (e.g., compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments